Please ensure Javascript is enabled for purposes of website accessibility

Tilray Strikes Deal to Export Medical Marijuana to the U.K.

By Eric Volkman - Feb 9, 2021 at 7:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's organic medicine should become available within weeks.

Tilray's (TLRY) medical marijuana products will soon be available in the U.K. The Canadian company announced Tuesday that it has reached an agreement with British company Grow Pharma, under which the latter will import Tilray's green medicine into the country. The financial terms of the deal were not disclosed.

The company said it expects its goods to become available in the U.K. by March.

As with several other European countries, marijuana consumption and use in the U.K. is allowed only by people who have been expressly granted permission to do so. The authority in this case is the country's National Health Service.

"As demand continues to ramp up in the UK, Tilray is well-positioned to be a leading supplier of medical cannabis products," the company quoted the managing director of Tilray Europe, Sascha Mielcarek, as saying.

"Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients' quality of life," he added.

Doctor pointing to a pile of cannabis flower on a desk.

Image source: Getty Images.

International expansion is important to Tilray, and this new agreement fits into these ambitions. The company already has a 2.7 million-square-foot facility located in Portugal, in which it grows and cultivates product. It was recently granted authorization to sell medical marijuana in the country, and has signed a deal similar to the U.K. arrangement under which it is shipping cannabis to neighboring Spain.

Tilray's growing European presence will complement that of Aphria (APHA), the company with which it is set to merge. Aphria operates a medical marijuana distribution company in Germany called CC Pharma, which has lately helped power its overall growth.

On Tuesday, generally an excellent day for marijuana stocks, Tilray rose a very robust 40.7%, against a slight dip in the S&P 500 index.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY
Aphria Stock Quote
Aphria
APHA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.